

Pierre Wolkenstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1530295/publications.pdf>

Version: 2024-02-01

184
papers

10,333
citations

38742

50
h-index

36028

97
g-index

198
all docs

198
docs citations

198
times ranked

6968
citing authors

#	ARTICLE	IF	CITATIONS
1	SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis. <i>Journal of Investigative Dermatology</i> , 2000, 115, 149-153.	0.7	850
2	Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 596-601.	1.2	559
3	Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. <i>Lancet, The</i> , 1998, 352, 1586-1589.	13.7	414
4	Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. <i>Lancet, The</i> , 2008, 372, 639-645.	13.7	329
5	Quality of life impairment in hidradenitis suppurativa: A study of 61 cases. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 621-623.	1.2	325
6	Severe cutaneous adverse reactions to drugs. <i>Lancet, The</i> , 2017, 390, 1996-2011.	13.7	293
7	Association between benign and malignant peripheral nerve sheath tumors in NF1. <i>Neurology</i> , 2005, 65, 205-211.	1.1	274
8	Elevated Risk for MPNST in NF1 Microdeletion Patients. <i>American Journal of Human Genetics</i> , 2003, 72, 1288-1292.	6.2	271
9	Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Contact Dermatitis</i> , 1996, 35, 234-236.	1.4	260
10	Neurological complications of neurofibromatosis type 1 in adulthood. <i>Brain</i> , 1999, 122, 473-481.	7.6	245
11	Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 51-57.	1.2	244
12	Combination Therapy with Clindamycin and Rifampicin for Hidradenitis Suppurativa: A Series of 116 Consecutive Patients. <i>Dermatology</i> , 2009, 219, 148-154.	2.1	222
13	NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. <i>Human Mutation</i> , 2010, 31, E1506-E1518.	2.5	208
14	Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>British Journal of Dermatology</i> , 2010, 163, 847-853.	1.5	204
15	Identification of Three Hidradenitis Suppurativa Phenotypes: Latent Class Analysis of a Cross-Sectional Study. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1506-1511.	0.7	187
16	Quality-of-Life Impairment in Neurofibromatosis Type 1. <i>Archives of Dermatology</i> , 2001, 137, 1421-5.	1.4	177
17	Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. <i>Intensive Care Medicine</i> , 1997, 23, 1237-44.	8.2	163
18	<i>NF1</i> Molecular Characterization and Neurofibromatosis Type I Genotype-Phenotype Correlation: The French Experience. <i>Human Mutation</i> , 2013, 34, 1510-1518.	2.5	140

#	ARTICLE	IF	CITATIONS
19	Neurofibromatosis type 1: from genotype to phenotype. <i>Journal of Medical Genetics</i> , 2012, 49, 483-489.	3.2	133
20	Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. <i>British Journal of Dermatology</i> , 2015, 173, 1142-1155.	1.5	132
21	Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. <i>Human Molecular Genetics</i> , 2009, 18, 2768-2778.	2.9	129
22	Intrinsic Defect in Keratinocyte Function Leads to Inflammation in Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1768-1780.	0.7	129
23	Impact of neurofibromatosis 1 on Quality of Life: A cross-sectional study of 176 American cases. <i>American Journal of Medical Genetics, Part A</i> , 2006, 140A, 1893-1898.	1.2	121
24	Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. <i>British Journal of Dermatology</i> , 2013, 169, 1223-1232.	1.5	121
25	Acne prevalence and associations with lifestyle: a cross-sectional online survey of adolescents/young adults in 7 European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 298-306.	2.4	115
26	Therapeutic management of DRESS: A retrospective study of 38 cases. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 246-252.	1.2	110
27	Role of Noncoding RNA ANRIL in Genesis of Plexiform Neurofibromas in Neurofibromatosis Type 1. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1713-1722.	6.3	106
28	Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1. <i>British Journal of Dermatology</i> , 2005, 153, 79-82.	1.5	104
29	Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study. <i>British Journal of Dermatology</i> , 2015, 173, 50-58.	1.5	104
30	SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. <i>Journal of Medical Genetics</i> , 2009, 46, 425-430.	3.2	103
31	Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. <i>British Journal of Dermatology</i> , 2013, 169, 1041-1048.	1.5	99
32	Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?. <i>European Journal of Human Genetics</i> , 2015, 23, 596-601.	2.8	97
33	Mortality Associated with Neurofibromatosis 1: A Cohort Study of 1895 Patients in 1980-2006 in France. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 18.	2.7	96
34	Toxic epidermal necrolysis, DRESS, AGEP: Do overlap cases exist?. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 72.	2.7	96
35	Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 37.	2.7	96
36	Bacteremia in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Medicine (United States)</i> , 2010, 89, 28-36.	1.0	80

#	ARTICLE	IF	CITATIONS
37	Cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S5-S13.	1.1	79
38	Psoriasis in France and Associated Risk Factors: Results of a Case-Control Study Based on a Large Community Survey. <i>Dermatology</i> , 2009, 218, 103-109.	2.1	76
39	Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients. <i>American Journal of Medical Genetics, Part A</i> , 2005, 132A, 49-53.	1.2	73
40	Health-Related Quality of Life in Patients with Neurofibromatosis Type 1. <i>Dermatology</i> , 2009, 218, 215-220.	2.1	73
41	Acute Respiratory Failure in Patients With Toxic Epidermal Necrolysis. <i>Critical Care Medicine</i> , 2014, 42, 118-128.	0.9	72
42	Association Between Mediterranean Anti-inflammatory Dietary Profile and Severity of Psoriasis. <i>JAMA Dermatology</i> , 2018, 154, 1017.	4.1	70
43	mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. <i>Neuro-Oncology</i> , 2014, 16, 493-504.	1.2	67
44	Evolving Pattern with Age of Cutaneous Signs in Neurofibromatosis Type 1: A Cross-Sectional Study of 728 Patients. <i>Dermatology</i> , 2011, 222, 269-273.	2.1	64
45	The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. <i>British Journal of Dermatology</i> , 2012, 167, 555-562.	1.5	64
46	Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant. <i>Medicine (United States)</i> , 2016, 95, e3033.	1.0	63
47	Neurofibromatosis 1-associated neuropathies: a reappraisal. <i>Brain</i> , 2004, 127, 1993-2009.	7.6	61
48	Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases. <i>British Journal of Dermatology</i> , 2009, 160, 844-848.	1.5	57
49	Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with <i>Nf1</i> Knockout in Boundary Cap Cells. <i>Cancer Discovery</i> , 2019, 9, 130-147.	9.4	57
50	Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22</i>	2.7	54
51	First-line Treatment of Pemphigus Vulgaris With a Combination of Rituximab and High-Potency Topical Corticosteroids. <i>JAMA Dermatology</i> , 2015, 151, 200.	4.1	48
52	Smoking and Dietary Factors Associated with Moderate-to-Severe Acne in French Adolescents and Young Adults: Results of a Survey Using a Representative Sample. <i>Dermatology</i> , 2015, 230, 34-39.	2.1	48
53	Clinical Risk Factors for Mortality in Patients With Neurofibromatosis 1. <i>Archives of Dermatology</i> , 2003, 139, 187-91.	1.4	47
54	Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. <i>Oncotarget</i> , 2016, 7, 35753-35767.	1.8	46

#	ARTICLE	IF	CITATIONS
55	Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. <i>Scientific Reports</i> , 2022, 12, 7140.	3.3	45
56	Usefulness of Screening Investigations in Neurofibromatosis Type 1. <i>Archives of Dermatology</i> , 1996, 132, 1333.	1.4	42
57	Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults. <i>British Journal of Dermatology</i> , 2017, 177, 212-222.	1.5	42
58	Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. <i>Archives of Dermatology</i> , 1996, 132, 1333-1336.	1.4	42
59	Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients Exposed/Unexposed and Propensity Score-Matched Analyses. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1293-1300.	0.7	41
60	Clinical and histologic features of <i>Mycoplasma pneumoniae</i> related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 110-117.	1.2	41
61	Consequences of Acne on Stress, Fatigue, Sleep Disorders and Sexual Activity: A Population-based Study. <i>Acta Dermato-Venereologica</i> , 2015, 95, 485-488.	1.3	38
62	Schwannomatosis: A Clinical Entity Distinct from Neurofibromatosis Type 2. <i>Dermatology</i> , 1997, 195, 228-231.	2.1	37
63	Hair follicle stem cell replication stress drives IFI16/STING-dependent inflammation in hidradenitis suppurativa. <i>Journal of Clinical Investigation</i> , 2020, 130, 3777-3790.	8.2	35
64	Prognostic value of histologic features of toxic epidermal necrolysis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, e29-e35.	1.2	34
65	Acute generalized exanthematous pustulosis: a retrospective audit of practice between 1994 and 2011 at a single centre. <i>British Journal of Dermatology</i> , 2015, 172, 1455-1457.	1.5	34
66	Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 524-529.	2.8	31
67	NF-1Score: A Prediction Score for Internal Neurofibromas in Neurofibromatosis-1. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2173-2178.	0.7	31
68	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>JAMA Dermatology</i> , 2015, 151, 302.	4.1	31
69	Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 437-440.	2.4	30
70	Different Patterns of Mast Cells Distinguish Diffuse from Encapsulated Neurofibromas in Patients with Neurofibromatosis 1. <i>Journal of Histochemistry and Cytochemistry</i> , 2011, 59, 584-590.	2.5	29
71	Sirolimus Improves Pain in NF1 Patients With Severe Plexiform Neurofibromas. <i>Pediatrics</i> , 2014, 133, e1792-e1797.	2.1	29
72	Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests. <i>Contact Dermatitis</i> , 2017, 77, 297-302.	1.4	29

#	ARTICLE	IF	CITATIONS
73	Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. <i>British Journal of Dermatology</i> , 2019, 180, 1206-1213.	1.5	29
74	Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf Dermatology</i> , 2020, 182, 618-624.	1.5	29
75	Clinical Characteristics of Pruritus in Neurofibromatosis 1. <i>Acta Dermato-Venereologica</i> , 2016, 96, 398-399.	1.3	28
76	The biology of cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S14-S20.	1.1	27
77	Dermatological emergencies: a comparative study of activity in 2000 and 2010. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 916-918.	2.4	26
78	Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. <i>British Journal of Dermatology</i> , 2015, 172, 400-405.	1.5	26
79	Breast cancer risk in neurofibromatosis type 1 is a function of the type of <i>NF1</i> gene mutation: a new genotype-phenotype correlation. <i>Journal of Medical Genetics</i> , 2019, 56, 209-219.	3.2	26
80	Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. <i>Genetics in Medicine</i> , 2020, 22, 398-406.	2.4	26
81	Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 286.	2.7	25
82	Visibility of Neurofibromatosis 1 and Psychiatric Morbidity. <i>Archives of Dermatology</i> , 2003, 139, 103.	1.4	24
83	Health-related quality of life and long-term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients. <i>British Journal of Dermatology</i> , 2020, 182, 916-926.	1.5	24
84	Current status and recommendations for biomarkers and biobanking in neurofibromatosis. <i>Neurology</i> , 2016, 87, S40-8.	1.1	23
85	Vulvovaginal sequelae in toxic epidermal necrolysis. <i>Journal of reproductive medicine, The</i> , 1997, 42, 153-6.	0.2	23
86	Association Between Severe Acute Contact Dermatitis Due to <i>Nigella sativa</i> Oil and Epidermal Apoptosis. <i>JAMA Dermatology</i> , 2018, 154, 1062.	4.1	22
87	Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with <i>de novo</i> carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 886-896.	5.1	22
88	Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus. <i>British Journal of Dermatology</i> , 2021, 185, 616-626.	1.5	22
89	Clinical characteristics predicting internal neurofibromas in 357 children with neurofibromatosis-1: results from a cross-sectional study. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 62.	2.7	20
90	Absence of Efficacy of Everolimus in Neurofibromatosis 1-Related Plexiform Neurofibromas: Results from a Phase 2a Trial. <i>Journal of Investigative Dermatology</i> , 2019, 139, 718-720.	0.7	19

#	ARTICLE	IF	CITATIONS
91	At-Risk Phenotype of Neurofibromatose-1 Patients: A Multicentre Case-Control Study. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 51.	2.7	18
92	Antitumour necrosis factor- γ therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. <i>British Journal of Dermatology</i> , 2016, 174, 667-670.	1.5	18
93	Severe cutaneous adverse reactions due to inappropriate medication use. <i>British Journal of Dermatology</i> , 2018, 179, 329-336.	1.5	17
94	Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017. <i>British Journal of Dermatology</i> , 2020, 182, 247-248.	1.5	16
95	Contact dermatitis caused by ascorbyl tetraisopalmitate in a cream used for the management of atopic dermatitis. <i>Contact Dermatitis</i> , 2014, 71, 60-61.	1.4	15
96	NF1 single and multi-exons copy number variations in neurofibromatosis type 1. <i>Journal of Human Genetics</i> , 2015, 60, 221-224.	2.3	15
97	Rituximab, a new treatment for difficult-to-treat chronic erythema multiforme major? Five cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1140-1143.	2.4	15
98	Dermatological emergencies: evolution from 2008 to 2014 and perspectives. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 274-279.	2.4	15
99	Acne across Europe: an online survey on perceptions and management of acne. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 463-466.	2.4	15
100	Severe Phenotype in Patients with Large Deletions of NF1. <i>Cancers</i> , 2021, 13, 2963.	3.7	15
101	Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1453-1455.	1.2	14
102	Individual- and hospital-level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012-2016. <i>British Journal of Dermatology</i> , 2020, 182, 900-906.	1.5	13
103	Agreement Between Self-reported Inflammatory Skin Disorders and Dermatologists'™ Diagnosis: A Cross-sectional Diagnostic Study. <i>Acta Dermato-Venereologica</i> , 2017, 97, 1243-1244.	1.3	12
104	Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 787-794.	2.4	12
105	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 843-852.	5.6	12
106	Creating a comprehensive research strategy for cutaneous neurofibromas. <i>Neurology</i> , 2018, 91, S1-S4.	1.1	11
107	Incidence of bloodstream infections and predictive value of qualitative and quantitative skin cultures of patients with overlap syndrome or toxic epidermal necrolysis: A retrospective observational cohort study of 98 cases. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 342-347.	1.2	11
108	Severe contact allergy to mupirocin in a polysensitized patient. <i>Contact Dermatitis</i> , 2019, 80, 397-398.	1.4	11

#	ARTICLE	IF	CITATIONS
109	Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas. <i>European Journal of Hospital Pharmacy</i> , 2020, 27, e48-e52.	1.1	11
110	Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience. <i>European Journal of Medical Genetics</i> , 2022, 65, 104386.	1.3	11
111	ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis. <i>European Journal of Human Genetics</i> , 2022, 30, 812-817.	2.8	11
112	Neurofibromatosis type 1: neurofibromas and sex. <i>British Journal of Dermatology</i> , 2016, 174, 402-404.	1.5	10
113	Renal replacement therapy during Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective observational study of 238 patients. <i>British Journal of Dermatology</i> , 2017, 176, 1370-1372.	1.5	10
114	Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series. <i>British Journal of Dermatology</i> , 2019, 180, 1234-1235.	1.5	10
115	A process modelling approach to assess the impact of teledermatology deployment onto the skin tumor care pathway. <i>International Journal of Medical Informatics</i> , 2021, 146, 104361.	3.3	10
116	Chronic pain: a long-term sequela of epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal) of <i>Dermatology and Venereology</i> , 2021, 35, 188-194.	2.4	10
117	High-concentration topical capsaicin in the management of refractory neuropathic pain in patients with neurofibromatosis type 1: a case series. <i>Current Medical Research and Opinion</i> , 2018, 34, 887-891.	1.9	9
118	Severe sequelae of erythema multiforme: three cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e34-e36.	2.4	9
119	Disabling ocular sequelae of epidermal necrolysis: risk factors during the acute phase and associated sequelae. <i>British Journal of Dermatology</i> , 2019, 181, 421-422.	1.5	9
120	Bladder Dysfunction in Children with Neurofibromatosis Type I: Report of Four Cases and Review of the Literature. <i>Urologia Internationalis</i> , 2018, 100, 339-345.	1.3	8
121	Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme. <i>JAMA Dermatology</i> , 2018, 154, 487.	4.1	8
122	Eruption of lymphocyte recovery with atypical lymphocytes mimicking a primary cutaneous T-cell lymphoma: a series of 12 patients. <i>Human Pathology</i> , 2018, 71, 100-108.	2.0	8
123	Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients. <i>Archives of Dermatology</i> , 1996, 132, 1333-6.	1.4	8
124	Epidermolysis bullosa acquisita-like eruption with anticollagen VII autoantibodies induced by penicillamine in Wilson disease. <i>British Journal of Dermatology</i> , 2014, 171, 1574-1576.	1.5	7
125	Facial Scars following Toxic Epidermal Necrolysis: Role of Adnexal Involvement?. <i>Dermatology</i> , 2016, 232, 220-223.	2.1	7
126	Epidermal necrolysis and autoimmune diseases: two more observations supporting the concept that "toxic" epidermal necrolysis can be "non-toxic". <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e360-e361.	2.4	7

#	ARTICLE	IF	CITATIONS
127	A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices. <i>British Journal of Dermatology</i> , 2018, 179, 1009-1011.	1.5	7
128	Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testing. <i>British Journal of Dermatology</i> , 2018, 179, 978-979.	1.5	7
129	Neurofibromatosis I and multiple sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 186.	2.7	7
130	Identifying challenges in neurofibromatosis: a modified Delphi procedure. <i>European Journal of Human Genetics</i> , 2021, 29, 1625-1633.	2.8	7
131	Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms. <i>European Journal of Dermatology</i> , 2021, 31, 372-380.	0.6	7
132	Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1359-1366.	2.4	7
133	Febrile ulceronecrotic Mucha Habermann disease mimicking aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: a diagnostic challenge. <i>European Journal of Dermatology</i> , 2018, 28, 834-835.	0.6	7
134	Bullous pemphigoid: Three main clusters defining 3 outcome profiles. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 359-365.	1.2	7
135	Facial transplantation: facing the limits, planning the future. <i>Lancet, The</i> , 2017, 389, 1293-1294.	13.7	6
136	Face transplantation: A longitudinal histological study focusing on chronic active and mucosal rejection in a series with long-term follow-up. <i>American Journal of Transplantation</i> , 2021, 21, 3088-3100.	4.7	6
137	S100B and neurofibromin immunostaining and Xâ€inactivation patterns of laserâ€microdissected cells indicate a multicellular origin of some NF1â€associated neurofibromas. <i>Journal of Neuroscience Research</i> , 2011, 89, 1451-1460.	2.9	5
138	Severe Cutaneous Adverse Reactions to Drugs: From Patients to the National Office for Compensation of Medical Accidents. <i>Dermatology</i> , 2014, 228, 338-343.	2.1	5
139	Toxic epidermal necrolysis: the past, the guidelines and challenges for the future. <i>British Journal of Dermatology</i> , 2016, 174, 1171-1173.	1.5	5
140	Skin biopsy polymerase chain reaction for rapid microbiological diagnosis in patients with purpura fulminans. <i>British Journal of Dermatology</i> , 2017, 177, e154-e155.	1.5	5
141	Dermatitis herpetiformis and bone mineral density: analysis of a French cohort of 53 patients. <i>European Journal of Dermatology</i> , 2017, 27, 353-358.	0.6	5
142	Very late sensitization to parabens induced by repeated applications of an anaesthetic therapeutic plaster to nonâ€damaged skin. <i>Contact Dermatitis</i> , 2018, 79, 194-195.	1.4	5
143	Cutaneous tests and interest of iobitridol in nonâ€immediate hypersensitivity to contrast media: a case series of 43 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e178-e180.	2.4	5
144	Combined Methotrexate and Alitretinoin for the treatment of difficultâ€toâ€treat generalized prurigo nodularis: a case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e516-e519.	2.4	5

#	ARTICLE	IF	CITATIONS
145	Lymphoproliferative malignancies in patients with neurofibromatosis 1. Orphanet Journal of Rare Diseases, 2021, 16, 230.	2.7	5
146	Patch tests in nonâ€immediate cutaneous adverse drug reactions: the importance of late readings on day 4. Contact Dermatitis, 2021, , .	1.4	5
147	Toxic epidermal necrolysis: The past, the guidelines and challenges for the future. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2016, 69, 733-735.	1.0	4
148	Patient-hospital communication: A platform to improve outpatient chemotherapy. , 2016, , .		4
149	Beard dermatitis induced by coloration. Contact Dermatitis, 2019, 81, 471-473.	1.4	4
150	Acute generalized exanthematous pustulosis and epidermal necrolysis differ in innate cytokine patterns. Clinical and Experimental Allergy, 2019, 49, 1258-1261.	2.9	4
151	Strong reactions to diltiazem patch tests: Plea for a low concentration. Contact Dermatitis, 2020, 83, 224-225.	1.4	4
152	Acute generalized exanthematous pustulosis induced by enoxaparin: 2 cases. Contact Dermatitis, 2021, 84, 280-282.	1.4	4
153	Relapsing generalized bullous fixed drug eruption: A severe and avoidable cutaneous drug reaction. Three case reports. Therapie, 2021, , .	1.0	4
154	Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1569-1576.	2.4	4
155	Dermatological emergency unit, dayâ€care hospital and consultations in time of COVIDâ€19: the impact of tele dermatology. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	4
156	Necrotizing fasciitis of the thigh revealing a Crohn's disease. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1648-1649.	2.4	3
157	Pemphigoid gestationis revealing a denial of pregnancy. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1411-1413.	2.4	3
158	Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone. Journal of Investigative Dermatology, 2017, 137, 1179-1181.	0.7	3
159	Hemostasis and Type 1 Neurofibromatosis. Plastic and Reconstructive Surgery - Global Open, 2017, 5, e1414.	0.6	3
160	Epidemiology of fragile skin: Internet-based surveys in Mexico and Russia. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 221-228.	1.8	3
161	Stevens-Johnson Syndrome During Pregnancy. JAMA Dermatology, 2018, 154, 224.	4.1	3
162	Nonâ€acral skin manifestations during the COVIDâ€19 epidemic: COVIDSKIN study by the French Society of Dermatology. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e539-e541.	2.4	3

#	ARTICLE	IF	CITATIONS
163	Lupus erythematosus and epidermal necrolysis: a case series of 16 patients. <i>British Journal of Dermatology</i> , 2022, 186, 372-374.	1.5	3
164	Erythema multiforme associated with anti-epilakin antibodies: a multicentric retrospective case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 0, , .	2.4	3
165	Nodules on a sternotomy scar. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 986.	9.1	2
166	First case of contact dermatitis caused by hydroxypropyl tetrahydropyrantriol used in an anti-ageing cream. <i>Contact Dermatitis</i> , 2017, 77, 60-61.	1.4	2
167	Primary cutaneous mucormycosis as a complication of erosive dermatitis: two cases. <i>European Journal of Dermatology</i> , 2018, 28, 227-229.	0.6	2
168	Iloprost: a potential alternative for skin graft-resistant hypertensive leg ulcer. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e726-e728.	2.4	2
169	Involvement of small-diameter nerve fibres in long-term chronic pain after Stevens-Johnson syndrome or toxic epidermal necrolysis. A neurophysiological assessment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e218-e221.	2.4	2
170	Essential oils as potential triggers for bullous pemphigoid? A report of two patients. <i>European Journal of Dermatology</i> , 2021, 31, 92-93.	0.6	2
171	Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis. <i>British Journal of Dermatology</i> , 2022, 186, 1037-1039.	1.5	2
172	Biases associated with epidermal necrolysis reporting in pharmacovigilance: An exploratory analysis using World Health Organization VigiBase. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 434-441.	1.9	2
173	Self-diagnosed drug allergies: the belief of patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e524-e526.	2.4	1
174	[18F]FDG Positron emission tomography with whole body magnetic resonance imaging ([18F]FDG-PET/MRI) as a diagnosis tool in Schwannomatosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 49.	2.7	1
175	Which patients present to dermatologic emergencies? A survey on 1561 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e583-e585.	2.4	1
176	Pityriasis lichenoides: a clinical and pathological case series of 49 patients with an emphasis on follow-up. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1561-1566.	1.3	1
177	Cervical cutaneous sclerosis: the stomach is not far from the skin. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e177-e179.	2.4	0
178	Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1344-1346.	3.8	0
179	The Heart in Neurofibromatosis 1. , 2021, , 87-109.		0
180	Urgences dermatologiques en réanimation : infections nosocomiales de la peau et des parties molles et toxidermies graves. <i>Medecine Intensive Reanimation</i> , 2018, 27, 461-474.	0.0	0

#	ARTICLE	IF	CITATIONS
181	Republication deÂ: Traitement des toxidermies graves. Journal Europeen Des Urgences Et De Reanimation, 2018, 30, 161-171.	0.1	0
182	Medical Follow-Up in Neurofibromatosis Type 1. , 2020, , 273-304.		0
183	Missed Diagnosis of Epilepsy-Associated Scald Burns: Two Cases Initially Diagnosed as Bullous Dermatitis. Journal of Burn Care and Research, 2021, 42, 569-572.	0.4	0
184	Identification of three clinical neurofibromatosis 1 subtypes: Latent class analysis of a series of 1351 patients. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 739-743.	2.4	0